Abstract
Antimicrobial resistance represents a significant challenge to future healthcare provision.An acronym ESKAPEE has been derived from the names of the organisms recognised as the major threats although there are a number of other organisms, notably Neisseria gonorrhoeae, that have become equally challenging to treat in the clinic. These pathogens are characterised by the ability to rapidly develop and/or acquire resistance mechanisms in response to exposure to different antimicrobial agents. A key part of the armoury of these pathogens is a series of efflux pumps, which effectively exclude or reduce the intracellular concentration of a large number of antibiotics, making the pathogens significantly more resistant. These efflux pumps are the topic of considerable interest, both from the perspective of basic understanding of efflux pump function, and its role in drug resistance but also as targets for the development of novel adjunct therapies. The necessity to overcome antimicrobial resistance has encouraged investigations into the characterisation of resistance-modifying efflux pump inhibitors to block the mechanisms of drug extrusion, thereby restoring antibacterial susceptibility and returning existing antibiotics into the clinic. A greater understanding of drug recognition and transport by multidrug efflux pumps is needed to develop clinically useful inhibitors, given the breadth of molecules that can be effluxed by these systems. This review discusses different bacterial EPIs originating from both natural source and chemical synthesis and examines the challenges to designing successful EPIs that can be useful against multidrug resistant bacteria.
Keywords: Antimicrobial resistance, Efflux Pump Inhibitors, Rational Drug Design, Medicinal Chemistry Optimisation, Multiple efflux systems, Computational approaches.
Current Medicinal Chemistry
Title:Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps
Volume: 23 Issue: 10
Author(s): Hannah Y. Mahmood, Shirin Jamshidi, J. Mark Sutton and Khondaker M. Rahman
Affiliation:
Keywords: Antimicrobial resistance, Efflux Pump Inhibitors, Rational Drug Design, Medicinal Chemistry Optimisation, Multiple efflux systems, Computational approaches.
Abstract:
Antimicrobial resistance represents a significant challenge to future healthcare provision.An acronym ESKAPEE has been derived from the names of the organisms recognised as the major threats although there are a number of other organisms, notably Neisseria gonorrhoeae, that have become equally challenging to treat in the clinic. These pathogens are characterised by the ability to rapidly develop and/or acquire resistance mechanisms in response to exposure to different antimicrobial agents. A key part of the armoury of these pathogens is a series of efflux pumps, which effectively exclude or reduce the intracellular concentration of a large number of antibiotics, making the pathogens significantly more resistant. These efflux pumps are the topic of considerable interest, both from the perspective of basic understanding of efflux pump function, and its role in drug resistance but also as targets for the development of novel adjunct therapies. The necessity to overcome antimicrobial resistance has encouraged investigations into the characterisation of resistance-modifying efflux pump inhibitors to block the mechanisms of drug extrusion, thereby restoring antibacterial susceptibility and returning existing antibiotics into the clinic. A greater understanding of drug recognition and transport by multidrug efflux pumps is needed to develop clinically useful inhibitors, given the breadth of molecules that can be effluxed by these systems. This review discusses different bacterial EPIs originating from both natural source and chemical synthesis and examines the challenges to designing successful EPIs that can be useful against multidrug resistant bacteria.
Export Options
About this article
Cite this article as:
Y. Mahmood Hannah, Jamshidi Shirin, Mark Sutton J. and M. Rahman Khondaker, Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps, Current Medicinal Chemistry 2016; 23 (10) . https://dx.doi.org/10.2174/0929867323666160304150522
DOI https://dx.doi.org/10.2174/0929867323666160304150522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Pharmacology of Current and Future Drugs for the Acute Treatment of Migraine: A Review and An Update
Current Clinical Pharmacology Novel Therapeutic Agents for Resistant Gram-Positive Infections
Current Drug Therapy COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Perspectives in Genomics The Future of Fungi in ‘omics’ era
Current Genomics Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Aquaporin and Vascular Diseases
Current Neuropharmacology Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Structure-Activity Relationship of Dicoumarol Derivatives as anti- Staphylococcus aureus (Staph Infection) Agents
Anti-Infective Agents Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Bacterial Sepsis and Chemokines
Current Drug Targets Treatment of Chronic Migraine with Intramuscular Pericranial Injections of Onabotulinumtoxin A
Recent Patents on CNS Drug Discovery (Discontinued) Advances and Patents about Medical Surgical Operation Skull Grinding Equipment
Recent Patents on Engineering Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice
Current Reviews in Clinical and Experimental Pharmacology Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Ivermectin in Human Medicine, An Overview of the Current Status of Its Clinical Applications
Current Pharmaceutical Biotechnology Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Aminoglycoside-Induced Ototoxicity
Current Pharmaceutical Design